Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.

ABSTRACT:

Objective

To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Methods

This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied.

Results

We included 990 patients from 15 hospitals. Eighty-four patient

SUBMITTER: Cortes-Vicente E 

PROVIDER: S-EPMC8862423 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature